TRAF3 mutations did not reach statistical significance, probably given the short size of the UHR MM subset, but in the MMRF’s CoMMpass cohort their presence predicted significantly improved outcomes as compared to TRAF3 wild-type patients (Fig. 5A-C). This evidence concerns the gene TRAF3 and Miyoshi myopathy.